At Vor Bio, we are working to change the way autoimmune diseases are treated. Our drug candidate, telitacicept, is designed to go beyond managing symptoms – it aims to stop the disease at its source.
In many autoimmune diseases, certain immune cells called B cells live longer than they should. These cells can then turn into plasma cells, which make harmful antibodies that attack the body instead of protecting it.
Telitacicept is uniquely designed to block two critical signals – BAFF and APRIL – that normally keep harmful B cells alive.
By turning down these signals, telitacicept has the potential to:
Unlike medicines that broadly suppress the immune system, telitacicept is designed to quiet only the harmful pathways while leaving the rest of the immune system ready to fight infections.
Our goal is simple: to create treatments that are safer, longer lasting, and truly-life changing for people with autoimmune diseases.
Telitacicept in Generalized Myasthenia Gravis (gMG)
The RemeMG Phase 3 global study is evaluating the efficacy, safety, and tolerability of telitacicept in patients with generalized myasthenia gravis (gMG).
The ongoing Phase 3 global trial is a randomized, double-blind, placebo-controlled study with an open-label extension.
